Effect of antifibrotic MicroRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related kidney fibrosis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Srivastava, Swayam Prakash ^a   Shi, Sen ^a   Kanasaki, Megumi ^a   Nagai, Takako ^a   Kitada, Munehiro ^a   He, Jianhua ^a   Nakamura, Yuka ^a   Ishigaki, Yasuhito ^a   Kanasaki, Keizo ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR 1; GAMMA INTERFERON; MICRORNA; OLIGOPEPTIDE; SERASPENIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BIOLOGICAL MODEL; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM CELL; FIBROSIS; GENETICS; HUMAN; KIDNEY; METABOLISM; MICROVASCULATURE; MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; DIABETES MELLITUS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 1; FIBROSIS; HUMANS; INTERFERON-GAMMA; KIDNEY; MICE; MICRORNAS; MICROVESSELS; MODELS, BIOLOGICAL; OLIGOPEPTIDES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84978898095     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29884     Document Type: Article

References (46)

1. Held P. J, et al. The United States Renal Data System?s 1991 annual data report: an introduction. Am J Kidney Dis 18, 1-16 (1991).
2. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nature reviews. Nephrology 7, 684-696, doi: 10.1038/nrneph.2011.149 (2011).
3. Kanasaki K, Taduri G, & Koya D. Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol (Lausanne) 4, 7, doi: 10.3389/fendo.2013.00007 (2013).
4. Kanasaki M, Nagai T, Kitada M, Koya D, & Kanasaki K. Elevation of the anti-fibrotic peptide N-Acetyl-seryl-Aspartyl-lysylproline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis & tissue repair 4, 25, doi: 10.1186/1755-1536-4-25 (2011).
5. Kanasaki K, et al. N-Acetyl-seryl-Aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. Journal of the American Society of Nephrology: JASN 14 863-872 (2003).
6. Shibuya K, et al. N-Acetyl-seryl-Aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/.db mice. Diabetes 54 838-845 (2005).
7. Omata M, et al. N-Acetyl-seryl-Aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. Journal of the American Society of Nephrology: JASN 17 674-685, doi: 10.1681/ASN.2005040385 (2006).
8. Liu J. M, et al. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101, 3014-3020 (2003).
9. Wang D, et al. N-Acetyl-seryl-Aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 287 H2099-H2105 (2004).
10. Fromes Y, Liu J. M, Kovacevic M, Bignon J, & Wdzieczak-Bakala J. The tetrapeptide acetyl-serine-Aspartyl-lysine-proline improves skin flap survival and accelerates wound healing. Wound Repair Regen 14, 306-312 (2006).
11. Huff T, Muller C. S, Otto A. M, Netzker R, & Hannappel E. beta-Thymosins, small acidic peptides with multiple functions. The international journal of biochemistry & cell biology 33, 205-220 (2001).
12. Philp D, Huff T, Gho Y. S, Hannappel E, & Kleinman H. K. The actin binding site on thymosin beta4 promotes angiogenesis. The FASEB journal 17, 2103-2105, doi: 10.1096/fj.03-0121fje (2003).
13. Malinda K. M, Goldstein A. L, & Kleinman H. K. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. The FASEB journal 11, 474-481 (1997).
14. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445, 177-182, doi: 10.1038/nature05383 (2007).
15. Nagai T, et al N-Acetyl-seryl-Aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition. Biomed Res Int 2014 doi: 10.1155/2014/696475 (2014).
16. Zeisberg E. M, et al. Endothelial-To-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13, 952-961 (2007).
17. Zeisberg E. M, Potenta S. E, Sugimoto H, Zeisberg M, & Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-Tomesenchymal transition. Journal of the American Society of Nephrology: JASN 19, 2282-2287 (2008).
18. Kanasaki K, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-To-mesenchymal transition in a therapeutic regimen. Diabetes 63, 2120-2131, doi: 10.2337/db13-1029 (2014).
19. He J, Xu Y, Koya D, & Kanasaki K. Role of the endothelial-To-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol. doi: 10.1007/s10157-013-0781-0 (2013).
20. Li J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocininduced diabetic nephropathy. Diabetes 59, 2612-2624, doi: 10.2337/db09-1631 (2010).
21. von Websky K, Reichetzeder C, & Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens 23, 54-60, doi: 10.1097/01.mnh.0000437542.77175.a0 (2014).
22. Panchapakesan U, Mather A, & Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond) 124, 17-26, doi: 10.1042/CS20120167 (2013).
23. Kirino Y, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-Type and DPP4-deficient rats. J Endocrinol 200, 53-61, doi: 10.1677/JOE-08-0424 (2009).
24. Srivastava S. P, Koya D, & Kanasaki K. MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT. Biomed Res Int 2013, 125469, doi: 10.1155/2013/125469 (2013).
25. Nagai T, et al. N-Acetyl-seryl-Aspartyl-lysyl-proline inhibits diabetes-Associated kidney fibrosis and endothelial-mesenchymal transition. Biomed Res Int 2014 696475, doi: 10.1155/2014/696475 (2014).
26. Sugimoto H, Grahovac G, Zeisberg M, & Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56, 1825-1833, doi: 10.2337/db06-1226 (2007).
27. Shi S, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-To-mesenchymal transition. Kidney Int. doi: 10.1038/.ki.2015.103 (2015).
28. Chen P. Y, et al. FGF regulates TGF-beta signaling and endothelial-To-mesenchymal transition via control of let-7 miRNA expression. Cell Rep 2, 1684-1696, doi: 10.1016/j.celrep.2012.10.021 (2012).
29. Stramer B. M, Mori R, & Martin P. The inflammation-fibrosis link?. A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol 127, 1009-1017, doi: 10.1038/sj.jid.5700811 (2007).
30. Fielding C. A, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40-50, doi: 10.1016/j. immuni.2013.10.022 (2014).
31. Apalset E. M, et al. Interferon gamma (IFN-gamma)-mediated inflammation and the kynurenine pathway in relation to risk of hip fractures: the Hordaland Health Study. Osteoporos Int 25, 2067-2075, doi: 10.1007/s00198-014-2720-7 (2014).
32. Kanasaki K, Nagai T, Nitta K, Kitada M, & Koya D. N-Acetyl-seryl-Aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Front Pharmacol 5, 70, doi: 10.3389/fphar.2014.00070 (2014).
33. Ma F, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 12, 861-869, doi: 10.1038/ni.2073 (2011).
34. Peng H, Carretero O. A, Peterson E. L, & Rhaleb N. E. Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Am J Physiol Heart Circ Physiol 298, H1357-H1364 (2010).
35. Zuo Y, et al. Thymosin beta4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int 84, 1166-1175, doi: 10.1038/ki.2013.209 (2013).
36. Macconi D, et al. MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. Journal of the American Society of Nephrology: JASN 23, 1496-1505, doi: 10.1681/ASN.2011121144 (2012).
37. Li P, et al. Angiotensin-converting enzyme N-Terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol 177, 1113-1121, doi: 10.2353/ajpath.2010.081127 (2010).
38. Lorenzen J. M, Haller H, & Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nature reviews. Nephrology 7, 286-294, doi: 10.1038/nrneph.2011.26 (2011).
39. Du B, et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS letters 584, 811-816, doi: 10.1016/j.febslet.2009.12.053 (2010).
40. Chung A. C, & Lan H. Y. MicroRNAs in renal fibrosis. Frontiers in physiology 6, 50, doi: 10.3389/fphys.2015.00050 (2015).
41. Kato M, Arce L, & Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clinical journal of the American Society of Nephrology: CJASN 4, 1255-1266, doi: 10.2215/CJN.00520109 (2009).
42. Wang B, & Ricardo S. Role of microRNA machinery in kidney fibrosis. Clinical and experimental pharmacology & physiology 41, 543-550, doi: 10.1111/1440-1681.12249 (2014).
43. Pezzolesi M. G, et al. Circulating TGF-beta1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes. Diabetes, doi: 10.2337/db15-0116 (2015).
44. Blahna M. T, & Hata A. Smad-mediated regulation of microRNA biosynthesis. FEBS letters 586, 1906-1912, doi: 10.1016/j. febslet.2012.01.041 (2012).
45. Wang B, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. Journal of the American Society of Nephrology: JASN 23, 252-265, doi: 10.1681/ASN.2011010055 (2012).
46. Qin W, et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. Journal of the American Society of Nephrology: JASN 22, 1462-1474, doi: 10.1681/ASN.2010121308 (2011).